{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:02:08Z","timestamp":1789502528767,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>\n                    Metformin-associated lactic acidosis (MALA) was a rare but important adverse event of metformin therapy and carried a high mortality rate. In most of reported cases, MALA occurred because of one or more patient associated contraindications for the drug were overlooked. The aim of this study was to evaluate the clinical outcome of MALA patients between the avoidable, unpredictable or combined metformin contraindications. During the study period, 91 patients with MALA and admitted to intensive care unit were enrolled in the study. Most patients had combined metformin contraindications (n\u2005=\u200547), followed by groups of unpredictable (n\u2005=\u200536) and avoidable (n\u2005=\u20058). The distribution of most selected outcomes between avoidable, unpredictable, and combined metformin contraindications had no significant statistical difference between these 3 groups. Only patients with vasoactive support presented the significant difference between 3 groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.0149). In addition, the association between each outcome and 3 metformin contraindications groups indicated no statistical difference. In conclusion, for patients with metformin contraindications which were avoidable, unpredictable or combined avoidable and unpredictable, there was no significant difference of clinical outcome. Therefore, MALA prognosis may not be related to the metformin therapy for different types of metformin contraindications.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045197","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:52Z","timestamp":1762211092000},"page":"e45197","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Metformin use despite contraindications in metformin-associated lactic acidosis"],"prefix":"10.1097","volume":"104","author":[{"given":"Chun-Chieh","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuei-Ling","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Therapy, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jia","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Feng","family":"Weng","sequence":"additional","affiliation":[{"name":"Departments of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-8477","authenticated-orcid":false,"given":"Chung-Han","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"Department of Information Management, Southern Taiwan University of Science and Technology, Tai-nan, Taiwan"},{"name":"Cancer Center, Taipei Municipal Wanfang Hospital, Taipei Medical University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00003246-198306000-00012","article-title":"Serial lactate determinations during circulatory shock.","volume":"11","author":"Vincent","year":"1983","journal-title":"Crit Care Med"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9610(97)89552-9","article-title":"Serial blood lactate levels can predict the development of multiple organ failure following septic shock.","volume":"171","author":"Bakker","year":"1996","journal-title":"Am J Surg"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.TA.0000140835.65944.54","article-title":"Predictors of patients who will develop prolonged occult hypoperfusion following blunt trauma.","volume":"57","author":"Schulman","year":"2004","journal-title":"J Trauma"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00005373-199310000-00014","article-title":"Lactate clearance and survival following injury.","volume":"35","author":"Abramson","year":"1993","journal-title":"J Trauma"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0735-6757(95)90043-8","article-title":"Correlation of serial blood lactate levels to organ failure and mortality after trauma.","volume":"13","author":"Manikis","year":"1995","journal-title":"Am J Emerg Med"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: a prognostic and therapeutic study.","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit Care Med"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002018-199920040-00006","article-title":"Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations.","volume":"20","author":"Lalau","year":"1999","journal-title":"Drug Saf"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00125-006-0316-2","article-title":"Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"49","author":"Nathan","year":"2006","journal-title":"Diabetologia"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2337\/diacare.21.10.1659","article-title":"Lactic acidosis rates in type 2 diabetes.","volume":"21","author":"Brown","year":"1998","journal-title":"Diabetes Care"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.22.6.925","article-title":"Incidence of lactic acidosis in metformin users.","volume":"22","author":"Stang","year":"1999","journal-title":"Diabetes Care"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin.","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2710.1998.00185.x","article-title":"Review of management of type 2 diabetes mellitus.","volume":"23","author":"Yap","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1464-5491.2005.01478.x","article-title":"Patients with Type 2 diabetes treated with metformin: prevalence of contraindications and their correlation with discontinuation.","volume":"22","author":"Rakovac","year":"2005","journal-title":"Diabetic Med"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1001\/jama.287.19.2504-a","article-title":"Frequency of inappropriate metformin prescriptions.","volume":"287","author":"Horlen","year":"2002","journal-title":"JAMA"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/archinte.162.4.434","article-title":"Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy.","volume":"162","author":"Calabrese","year":"2002","journal-title":"Arch Intern Med"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1464-5491.2001.00509.x","article-title":"Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.","volume":"18","author":"Emslie-Smith","year":"2001","journal-title":"Diabetic Medicine"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.20.6.925","article-title":"Contraindications to metformin therapy in patients with NIDDM.","volume":"20","author":"Sulkin","year":"1997","journal-title":"Diabetes Care"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-5491.1999.00115.x","article-title":"Contra-indications to metformin therapy are largely disregarded.","volume":"16","author":"Holstein","year":"1999","journal-title":"Diabetic Med"},{"key":"R20-20260915","first-page":"45","article-title":"Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review.","volume":"17","author":"Renda","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF02440866","article-title":"Metformin-associated lactic acidosis in Sweden 1977\u20131991.","volume":"44","author":"Wiholm","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/imj.12369","article-title":"Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?","volume":"44","author":"Huang","year":"2014","journal-title":"Intern Med J"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2710.2010.01192.x","article-title":"Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.","volume":"36","author":"van Berlo-van de Laar","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes:a report from the American Diabetes Association Workgroup on Hypoglycemia.","volume":"28","author":"Hypoglycemia","year":"2005","journal-title":"Diabetes Care"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates.","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/sim.3794","article-title":"Bias\u2010reduced and separation\u2010proof conditional logistic regression with small or sparse data sets.","volume":"29","author":"Heinze","year":"2010","journal-title":"Stat Med"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2044.2007.05371.x","article-title":"Metabolic acidosis in the critically ill: part 2. Causes and treatment.","volume":"63","author":"Morris","year":"2008","journal-title":"Anaesthesia"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11255-009-9549-6","article-title":"Impact of acute kidney injury on metformin-associated lactic acidosis.","volume":"41","author":"Wen","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMra1309483","article-title":"Lactic acidosis.","volume":"371","author":"Kraut","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1515\/cclm-2016-0438","article-title":"Lactic acidosis: an update.","volume":"55","author":"Seheult","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"e0273678","DOI":"10.1371\/journal.pone.0273678","article-title":"Metformin-associated lactic acidosis and factors associated with 30-day mortality.","volume":"17","author":"Thammavaranucupt","year":"2022","journal-title":"PLoS One"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"e29918","DOI":"10.1097\/MD.0000000000029918","article-title":"Clinical presentations and prognosis of metformin-associated lactic acidosis patients in the intensive care unit: a 20-year survey.","volume":"101","author":"Yang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R35-20260915","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/15563650.2019.1648816","article-title":"Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study.","volume":"58","author":"Corchia","year":"2020","journal-title":"Clin Toxicol"},{"key":"R36-20260915","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/hdi.13113","article-title":"Metformin\u2010associated lactic acidosis (MALA): is it an underestimated entity? A retrospective, single\u2010center case series.","volume":"28","author":"Kim","year":"2024","journal-title":"Hemodial Int"},{"key":"R37-20260915","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1002\/edm2.382","article-title":"New potential for an old kid on the block: impact of premorbid metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study.","volume":"6","author":"Van Moorter","year":"2023","journal-title":"Endocrinol Diabetes Metab"},{"key":"R38-20260915","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2337\/diacare.27.7.1791","article-title":"The phantom of lactic acidosis due to metformin in patients with diabetes.","volume":"27","author":"Misbin","year":"2004","journal-title":"Diabetes Care"},{"key":"R39-20260915","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2796.2003.01271.x","article-title":"Metformin and lactic acidosis: cause or coincidence? A review of case reports.","volume":"255","author":"Stades","year":"2004","journal-title":"J Intern Med"},{"key":"R40-20260915","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1503\/cmaj.045292","article-title":"Metformin\u2019s contraindications should be contraindicated.","volume":"173","author":"McCormack","year":"2005","journal-title":"CMAJ"},{"key":"R41-20260915","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/dom.12978","article-title":"Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: a GoDarts study.","volume":"19","author":"Connelly","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R42-20260915","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:41Z","timestamp":1789498961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":40,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045197","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}